Creeping Through the Backdoor: Disruption in Medicine and Health

Brendan Shaw¹,²,³ and Orin Chisholm³*

¹ Shawview Consulting, London, United Kingdom, ² Shawview Consulting, Sydney, NSW, Australia, ³ Pharmaceutical Medicine, School of Medical Sciences, UNSW Sydney, Sydney, NSW, Australia

Can disruption happen when no one notices? Disruptive technologies and processes are fundamentally starting to up-end how medicines and health systems benefit patients but the question is whether health systems are ready for them. This paper will briefly review the business strategy and management literature on topics such as disruption and “black swan” theories of change, before turning to discuss some of the areas where change is affecting medicine and healthcare. Such areas include the emergence of cell and gene therapies, the economics of cures, digital technologies, mobile apps, social media, supply chain technologies such as drones and online distribution, universal health coverage and funding, and consumerisation of healthcare. The question to be asked is whether these sorts of changes are “disruptive” or whether they were coming for a long time and it is just that health systems are slow to change. It could be argued that while perhaps unexpected by day-to-day practitioners in healthcare, in fact, many of the changes now starting to affect the health and medicines sector have been affecting other sectors such as technology, finance and communications for decades.

Keywords: disruption, healthcare, health systems, medicine, policy, innovation

INTRODUCTION

Even before the current total systemic disruption caused by the Covid-19 outbreak, health systems worldwide were increasingly confronted with immense change and disruption. But what does “disruption” actually mean and do health systems cope well with disruption? In fact, health systems are not well suited to dealing with disruptive change (Morris et al., 2011; Chaudoir et al., 2013) but they are not unique in this problem (Rogers, 2003). Much of the literature on disruption from the world of business is filled with examples of organizations that do not adapt to disruptive change very well (Wright et al., 2004; Burke, 2018). Given the scale of change sweeping society today, it is important to look at how adaptable our health systems are to change now and in the future.

WHAT IS DISRUPTION?

Innovation and disruption has become a major theme in business studies and management research. The term has been adopted across a range of fields to describe radical change that disrupts current paradigms. Stemming from earlier work by economists such as Joseph Schumpeter’s concept of “creative destruction,” Clayton Christensen has examined how disruptive innovation affects businesses and industrial sectors (Schumpeter, 1942; Spencer and Kirchhoff, 2006; Christensen et al., 2017).
While the term disruptive innovation is used at length, one problem is that the term has not been sufficiently defined in a number of disciplines. While scientific research, technological change, business development and other forms of innovation occur all the time, innovation that can be considered "disruptive" is that which up-ends the established order or way of doing things. In the context of healthcare, Christensen has defined disruption as "an innovation that makes things simpler and more affordable, and 'technology' is a way of combining inputs of materials, components, information, labor, and energy into outputs of greater value" (Christensen et al., 2017). However, this definition has been criticized because it fails to sufficiently differentiate what is disruptive and what is not (Weeks, 2015). Moreover, the experience in healthcare is that innovation does not always lead to more affordable technologies.

At one level innovation is part of the normal operation of health systems. Scientific research is constantly leading to more knowledge about health and disease; new medicines and medical devices are being developed; and new surgical and medical procedures are being incorporated into healthcare. Some of this innovation will provide substantial "breakthrough" technological improvements, some will be incremental improvements and some will provide little or no benefit. Evaluation systems like health technology assessment are often used to assess their benefit and cost-effectiveness for the health system (Caro et al., 2019).

Our definition is that disruption is where a change upsets current systems to such a point that the incumbents operating in that system cannot adapt to that change. Innovation and change happen all the time, and health systems are no exception to this. Our interest here is in how disruption upsets current systems, upends existing paradigms and allows outside entrants to enter the market and introduce substantive innovations, models or processes that radically shift the dynamics and accepted processes in a system that are not well anticipated or managed by the incumbents in a system.

THEORIES OF DISRUPTION

A key learning from the management literature is that organizations often find it difficult to embrace radical, disruptive innovations in their own business strategies (Wright et al., 2004; Burke, 2018). This can be due to companies' existing customers not wanting disruption and preferring a company's older products, processes and technologies (Christensen et al., 2015). This provides companies with the challenge of introducing innovations to attract new customers while maintaining their existing business and customer base (Markides and Oyon, 2010). Companies themselves might be reluctant to disrupt their existing profits, business models and processes that might still be earning good returns for the company today. Existing company frameworks and belief systems might also hold back the adoption of new processes and technologies (De Jong and Van Dijk, 2015).

While not necessarily a forgone conclusion, there are numerous examples of companies that failed to disrupt themselves in the face of emerging technological and business changes leaving the way open for competitors to take advantage (Ismael et al., 2014; Gans, 2016). Kodak and its failure to capitalize on its invention of the digital camera (Mui, 2012), Nokia’s failure to adapt to the mobile phone market (Birkinshaw, 2013), and Xerox failing to succeed in personal computers despite developing many of the core technologies (Wessel, 2012) are examples of this.

Uncertainty is also a problem, where a company or organization may have a range of potential technological options available but it is unclear which is the best choice. Decisions about the future must be made in the absence of perfect information (Nooraie, 2012), a problem complicated by the increasing pace of disruption compressing the timeframes available to embrace radical changes (Baghai et al., 2000; Scott et al., 2018). “Black swan theory” in the management literature explores the extent to which organizations and societies are ready to manage large or highly impactful events that are outside the bounds of what people would consider 'normal' (Taleb, 2007). Applied to risk management and decision making in business, this theory encourages companies to think outside their normal frame of reference in considering future scenarios (Le Merle, 2011; Ferguson, 2014).

Disruption is increasingly becoming a normal part of business strategic planning. This is triggered by a swathe of enabling technologies across sectors and novel business models introduced by new entrants with first-mover advantages over incumbent firms (Spencer and Kirchhoff, 2006). Examples include Uber in the hire taxi car business, Netflix in the on-demand television subscription market, Tesla in the automotive industry, and Amazon in the online and retail shopping sector (Voigt et al., 2017; Berger et al., 2018; Ives et al., 2019; Shipley, 2020).

WHAT DISRUPTIONS ARE OCCURRING IN THE HEALTH SYSTEM?

Our sense is that, after a slow start, disruptive change is starting to affect health systems around the world in many ways. Some of the changes now starting to impact the health sector have been disrupting other sectors in society for some time, but are now gathering momentum in the health sector: Artificial Intelligence (AI)/machine learning, quantum computing, blockchain, robotics and the Internet of Things (expect acceleration with the roll-out of 5G networks). There are suggestions that the pace of disruption will increase in healthcare as in other sectors of the economy and society. This may be due to fundamental structural changes including technological change in things like nanotechnology, quantum computing and robotics, or changes in consumer behavior, such as a greater focus on self-help, access to information and social connection (Deloitte Center for Health Solutions, 2019).

Technological Changes

Many of the changes disrupting healthcare stem from technological change. For example, new cell and gene therapies which offer
potential cures but also raise challenges for regulatory agencies and payers (Schaffer et al., 2018; Anguela and High, 2019; Faulkner et al., 2019; Jonsson et al., 2019). The growth in AI, machine learning and big data in healthcare has the potential to disrupt the science and economics of drug development and healthcare in various ways (Harrer et al., 2019; Topol, 2019; Joshi et al., 2020; World Health Organisation, 2020). Examples include tracking population outcomes, tracking health epidemics such as thunderstorm asthma and the Covid-19 outbreak or improving clinical trials and drug development. The recent publication of Deep Mind’s AI predicting the shape of proteins faster than humans (Senior et al., 2019), the commencement of clinical trials for a new influenza vaccine developed using AI (Masige, 2019) or the use of machine neural learning networks to identify new antibiotics or optimize orthopedic surgery (see Box 1) show the potential of this technology. Internet-based technologies such as blockchain are predicted to provide opportunities for health system functionality and efficiency by developing new payment mechanisms, improving the integrity of medical records and upgrading supply-chain integrity (Halamka et al., 2019). 3D-printed pills have already received FDA approval (FDA, 2015; Stokel-Walker, 2019; Tangermann, 2019) and, as they become more mainstream, may disrupt traditional delivery and supply systems of medicines. Novel drug-device combinations are entering the market such as Abilify MyCite (aripiprazole pill with ingestible event marker sensor to track compliance), approved by the FDA in 2017 (Otsuka Pharmaceuticals, 2017). This will disrupt tracking of compliance in certain patient populations (Velligan et al., 2019).

**Economic Changes**

Systems of health technology assessment may be forced to reconsider conventional value assessment and reward models because health system management has not anticipated the impact of the rapid evolution of breakthrough therapies (Faulkner et al., 2019). While the latest generation of hepatitis C medicines were evaluated as cost-effective, some governments had difficulties in structuring their policies, diagnostic and financing systems to manage the budgetary impact (World Health Organisation, 2018). New payment models such as subscription-based ‘Netflix’-type models and others have been proposed (Moon and Erickson, 2019; The Economist, 2019).

The potential for rapid disruption in the supply chains for medicines, blood supply and other health services has increased with the entry of disruptors from other sectors outside healthcare such as Amazon’s purchase of PillPack (Baum, 2018), Google buying FitBit (Berg, 2019; Lovett and Muxio, 2019) or Alphabet’s drug development partnerships (GSK, 2016; Pharma Letter, 2019). Rapid development and falling costs in drone technology means that these are increasingly being utilised to deliver healthcare products and services (Amukele, 2020; Ochieng et al., 2020), be it the delivery of vaccines to remote health clinics in Vanuatu, blood supplies in Rwanda, or insulin to remote towns in Ireland, disrupting traditional supply chains (The Lancet Haematology, 2017; McVeigh, 2018; McGrath, 2019; Poljak and Šterbenc, 2019). Thermostable vaccines will also disrupt supply chain models (Lee et al., 2017). Such technologies, along with the rise in innovative models for public-private partnerships will deliver benefits to public health (National Academies, 2019). We are already starting to see this in the Covid-19 pandemic (Mullin, 2020).

**Societal Changes**

Societal and environmental disruption is affecting healthcare. For example, the growing use of social media by patients and doctors alike (George et al., 2013) has potential benefits through improved patient information and public health research. However, social media also carries significant risks through the spread of disinformation such as the rise of anti-vaccination groups; the recent Samoa measles outbreak being a case in point (McNamara, 2019). A call from the Director-General of the World Health Organization (WHO) for a collective effort to combat the promotion of misinformation about vaccines through social media signals how problematic this disruption has become for healthcare (WHO, 2019a). Similarly, climate change is listed by the WHO as one of the top ten threats to human health in 2019 (WHO, 2019b). There is growing recognition that climate change is creating major challenges for healthcare systems, be it through the rise of mosquito-borne infectious tropical diseases in countries where these have historically been absent (Franklinos et al., 2019), such as the rise of West Nile virus in Germany (Wyatt, 2019), or the rise of malnutrition and heat stress (World Medical Association, 2019).

Covid-19 has accelerated the roll-out of services that reduce face-to-face interactions in healthcare. For example, video consultations between doctors and patients have been rapidly implemented in Australia, over a couple of weeks (Greenhalgh et al., 2020); see Box 2 for further examples.
All too often, health systems are themselves the cause of the disruptions they are facing. The healthcare sector is typically slow to adapt to new technologies, as illustrated by the slow adoption of AI in healthcare (Masoudi and Wang, 2019; Gans, 2016). One of the reasons for this is the institutions’ internal incentives, such as the reluctance of incumbent private companies to invest in new technologies. However, the Covid-19 outbreak has shown that health systems can be forced to adopt new technologies and practices in a very short period of time. This is an important lesson for the future of healthcare, as governments and other stakeholders will need to consider how to ensure that health systems are prepared for future disruptive challenges.
Uber. Will patients and public policy makers welcome or push back against the entry of new private sector players in healthcare?

Just as in other sectors of the economy where organizations have had to adapt to change, actors in the health sector will need to improve their adaptability to change. Governments will need to become more adept at managing regulatory and policy challenges that open up new opportunities. Payers will be confronted with radical new medical treatments that challenge traditional financing systems but save money over the long-term. Pharmaceutical and device companies will be threatened by new entrants into healthcare from outside the sector but could also build new business. Healthcare professionals may be challenged by new technologies that undermine old treatment pathways but create new ones and patients may be confronted by new tests or data that seem threatening but deliver greater quality of life.

How and why health systems manage such disruption will vary depending on factors such as the level of public versus private funding, the relative roles of different actors in the sector, the degree of institutionalization and legacy in the system, the relative level of resources in a country, the extent to which a country's health system is internationalized and population characteristics and needs.

Several areas of further research emerge from this overview. Firstly, a clearer definition of disruptive innovation is needed, particularly in the healthcare setting. While various clarifications have been suggested the ongoing debate about what disruptive innovation actually is suggests further refinement is needed around this definition (Hwang and Christensen, 2008; Kirsch, 2019). Moreover, further research to understand what types of health systems are best able to cope with, manage and utilize disruptive innovation would be beneficial (Hwang and Christensen, 2008; Broska et al., 2019; Deloitte Center for Health Solutions, 2019; Gaddam, 2019).

**REFERENCES**

360 Knee Systems (2020). https://kneesystems.com/, accessed 24/3/2020.
Akinola, S., and Dimitrova, D. (2019). Seven ways the private sector can contribute to universal health coverage. World Economic Forum, 20 September, https://www.weforum.org/agenda/2019/09/7-ways-the-private-sector-can-contribute-to-universal-health-coverage, accessed 17/12/2019.
Amuoke, T. (2020). The economics of medical drones. Lancet Global Health 8 (1), e22. doi: 10.1016/S2214-109X(19)30494-2, accessed 17/12/2019.
Anguela, X. M., and High, K. A. (2019). Entering the modern era of gene therapy. Ann. Rev. Med. 70, 273–288. doi: 10.1146/annurev-med-012017-043332
Baghai, M., Coley, S., and White, D. (2000). The alchemy of growth: practical insights for building the enduring enterprise (YSA: Perseus Books).
Baum, S. (2018). Amazon will acquire PillPack, ending months of speculation. MedCityNews, 28 June, https://medcitynews.com/2018/06/amazon-will-acquire-pillpack/, accessed 17/12/2019.
Berg, J. (2019). Why Google is buying Fitbit. New York, USA: MedCityNews, 1 November, https://medcitynews.com/2019/11/why-google-is-buying-fitbit, accessed 17/12/2019.
Berger, T., Chen, C., and Frey, C. B. (2018). Drivers of disruption? Estimating the Uber effect. Eur. Econom. Rev. 110, 197–210. doi: 10.1016/j.eurocorev.2018.05.006
Birkshaw, J. (2013). Why corporate giants fail to change. Fortune 8 May, https://fortune.com/2013/05/08/why-corporate-giants-fail-to-change/, accessed 24/10/2019.
Bodkin, H. (2018). NHS world’s biggest fax machine buyer due to “stubborn” resistance to new technology, say medical leaders (London, UK: The Telegraph). 12 July, https://www.telegraph.co.uk/news/2018/07/11/nhs-worlds-biggest-fax-machine-buyer-due-stubborn-resistance/, accessed 17/12/2019.
Broska, L., Poganietz, W., and Vögele, S. (2019). Extreme Events Defined: A Conceptual Discussion Applying a Complex Systems Approach. Futures 115, 102490. doi: 10.1016/j.futures.2019.102490. accessed 18/3/2020.
Burke, W. W. (2018). Organizational change – Theory and Practice. 5th edition (USA: Sage Publishing).
Caro, J., Brazier, J., Karnon, J., Kolominsky-Rabas, P., McGuire, A., Nord, E., et al. (2019). Determining value in health technology assessment: stay the course or tack away? Pharmacoeconomics 37, 293–299. doi: 10.1007/s40273-018-0742-2
Castle-Clark, S. (2018). What will new technology mean for the NHS and its patients?: four big technological trends (London: The Health Foundation, Institute for Fiscal Studies, The Kings Fund, Nuffield Trust), 3, accessed 17/12/2019.
Chaudoir, S. R., Dugan, A. G., and Barr, C. H. I. (2013). Measuring factors affecting implementation of healthcare innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. Implementation Sci. 8, 42–42. doi: 10.1186/1748-5908-8-22
Cheng, V. C., Lau, S. K., Woo, P. C., and Yuen, K. Y. (2007). Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20 (4), 660–694. doi: 10.1128/CMR.00023-07
Christensen, C., Raynor, M., and McDonald, R. (2015). What is disruptive innovation? Harvard Business Rev. December, https://hbr.org/2015/12/what-is-disruptive-innovation, accessed 24/10/2019.

**CONCLUSIONS**

As the current Covid-19 outbreak is graphically demonstrating, disruption in health often happens in spite of, not because of, the structures and processes of health systems. Disruptive innovation provides both challenges and opportunities in healthcare. While raising many issues that are, at times, confrontational for health systems, disruption can cause problems but also provide new solutions. The challenge is in being able to adapt, encourage, and respond to such change.

Many of the disruptive forces now starting to affect health systems have been building for some time, as evidenced by their earlier emergence in other sectors of the economy and society and such changes will continue to trigger rapid and dramatic changes in healthcare.

All players in the health system, be they governments, payers, patients, healthcare professionals, providers and technology developers have valid roles in managing and adopting disruptive changes in healthcare, as demonstrated by their responses to the recent Covid-19 outbreak. The challenge is for those players in the health sector to recognize and capitalize on disruptive changes to the benefit of patients and the community worldwide while delivering a more efficient and effective health system for the 21st century and beyond. While potentially generating enormous opportunities for society, including better health, social development and economic growth, health systems and the participants in it need to be ready to anticipate, consider and embrace such changes as they come through the backdoor.

**AUTHOR CONTRIBUTIONS**

BS and OC were responsible for the concept and writing of this paper and take full accountability for the content.
Nooraie, M. (2012). Factors Influencing Strategic Decision-Making Processes. Int. J. Acad. Res. Bus Soc. Sci. 2 (7), 405–429.

Ochieng', W., Tun, Y., Scheel, C., Lau, C., Chadin, J., and Yee, S. (2020). Uncrewed aircraft systems versus motorcycles to deliver laboratory samples in West Africa: a comparative economic study. Lancet Global Health 8 (1), e143-51. doi: 10.1016/S2214-109X(19)30464-4, accessed 17/12/2019.

OECD (2019). Health in the 21st century: putting data to work for stronger health systems (Paris, France). Accessed 17/12/2019.

Osterholm, M. (2005). Preparing for the next pandemic. Foreign Affairs, 84 (4), 24–37. https://www.foreignaffairs.com/articles/2005-07-01/preparing-next-pandemic, accessed 7/5/2020.

Otsuka Pharmaceuticals (2017).

Philipkoski, K. (2020). 6 companies volunteering their 3D printing tech to protect medical workers and COVID-19 patients. Forbes. 30 April, https://www.forbes.com/sites/kristenphilipkoski/2020/04/30/3d-printing-companies-are-volunteering-their-tech-to-protect-medical-workers-and-covid-19-patients/, accessed 7/5/2020.

Poljak, M., and Sterbanc, A. (2019). Use of drones in clinical microbiology and infectious diseases: current status, challenges and barriers. Clin. Microbiol. Infect. S1198-743X (19), 30499-30499. doi: 10.1016/j.cmi.2019.09.014

Rogers, E. M. (2003). Diffusion of Innovations. 5th edition (NY, USA: Free Press).

Rose, E. (2017). Closure of Vodafone pager services sparks concern among nurses. Evening Standard. 11 May, https://www.standard.co.uk/news/uk/nurses-sound-alarm-over-closure-of-vodafone-pager-service-a353676.html, accessed 17/12/2019.

Schaffer, S. K., Messner, D., Mestre-Ferandiz, J., Tambor, E., and Towsie, A. (2018). Paying for cures: perspectives on solutions to the “affordability issue.” Value Health 21, 276–279. doi: 10.1016/j.jval.2017.12.013

Schumpeter, J. A. (1942).

Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., et al. (2019). Protein structure prediction using multiple deep neural networks in the 13th Protein Engineering Design and Selection Conference. Switzerland. https://www.who.int/emergencies/ten-threats-to-global-health-systems-report.pdf, accessed 24/3/2020.

Shaw, B., and Chisholm, O. (2019). Australia’s National Medicines Policy is outdated. BMJ. 321 (7262), 252–254.e1. doi: 10.5699/mj2018.702.

Shipley, L. (2020). How Tesla Sets Itself Apart. Harvard, USA: Innosight World Medical Association (2019).

Stokel-Walker, C. (2019). DIY drugs: should hospitals make their own medicine? Guardian. 15 October, https://www.theguardian.com/science/2019/oct/15/diy-drugs-should-hospitals-make-their-own-medicine, accessed 17/12/2019.

Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cabillo-Ruiz, A., Donghia, N. M., et al. (2020). A deep learning approach to antibiotic discovery. Cell 180, 688–702. doi: 10.1016/j.cell.2020.01.021, accessed 17/3/2020.

Stuckler, D., Feigl, A., Basu, S., and McKee, M. (2010). The political economy of universal health coverage. First global symposium on health systems research, Background paper. Montreux, Switzerland. http://healthsystemsresearch.org/hr/2010/images/stories/8political_economy.pdf, accessed 25/12/2019.

Taleb, N. (2007). The black swan: the impact of the highly improbable (London, UK: Penguin Books).

Tangemann, V. (2019). This start-up wants to 3D print one pill for all your prescriptions. futurism.com, blog, New York, USA. https://futurism.com/the-byte/3d-printed-pill-all-prescriptions, accessed 16/12/2019.

The Economist (2019). Netflix and pills – the antibiotic industry is broken. The Economist, 431 (9141), 16. https://www.economist.com/leaders/2019/05/04/antibiotic-industry-is-broken

The Lancet Haematology (2017). Look! Up in the sky! It’s a bird. It’s a plane. It’s a medical drone! Lancet Haematol. 4 (2), e56. doi: 10.1016/S2352-3026(17)30004-2

Topol, E. I. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56. doi: 10.1038/s41591-018-0300-7

Vellignan, D. L., Maples, N. J., Pokorny, J. L., and Wright, C. (2019). Assessment of adherence to oral antipsychotic medications: What has changed over the past decade? Schizophr. Res. S0920-9994 (19), 30529–30528. doi: 10.1016/j.schres.2019.11.022

Voigt, K.-i., Buliga, O., and Michl, K. (2017). “Entertainment on Demand: The Case of Netflix,” in Business Model Pioneers. Management for Professionals (Cham, Switzerland: Springer).

Webster, P. (2020). Virtual health care in the era of Covid-19. Lancet 39, 1180–1181.

Weeks, M. R. (2015). Is disruption theory wearing new clothes or just naked?: Analyzing recent critiques of disruptive innovation theory. Innovation: Management Policy Pract. 17 (4), 417–428. doi: 10.1080/14473938.2015.1061896, accessed 17/3/2020.

Wessel, M. (2012). Big companies can’t innovate half way. Harvard, USA: Harvard Business Review, 4 October, https://hbr.org/2012/10/big-companies-cant-innovate-halfway, accessed 24/10/2019.

World Health Organisation (2016). Implementation of the 2005 International Health Regulations: Report of the Review Committee on the role of the International Health Regulations (2005) in the Ebola outbreak and response. Geneva, Switzerland: Sixty-Ninth World Health Assembly, 13 May, A69/21, https://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_21-en.pdf파일을 얻은 1/5/2020.

World Health Organisation (2018). Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low- and Middle-Income Countries (Geneva, Switzerland). Accessed 18/3/2020.

World Health Organisation (2019a). WHO Director-General statement on the role of social media platforms in health information. Geneva, Switzerland News statement, 28 August, https://www.who.int/news-room/detail/28-08-2019-who-director-general-statement-on-the-role-of-social-media-platforms-in-health-information, accessed 17/12/2019.

World Health Organisation (2019b). Ten threats to global health in 2019. Geneva, Switzerland. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019, accessed 17/12/2019.

World Health Organisation (2020). Report of the WHO-China joint mission coronavirus disease 2019 (Covid-19). Geneva, Switzerland. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf, accessed 24/3/2020.

World Health Organisation (2019). Physicians demand accelerated action on climate change. Forney-Voiture, France Press release, 28 October, https://www.nmae.com/news-post/physicians-demand-accelerated-action-on-climate-change/, accessed 17/12/2019.

Wright, G., van de Heijden, K., Bradfield, R., Burt, G., and Cairns, G. (2004). The psychology of why organizations can be slow to adapt to change. J. Gen. Manage. 29 (4), 21–36. doi:10.1177/036635420402900402

Wyatt, T. (2019). West Nile virus reaches Germany in ‘sign of climate change’. Independent. 27 September, https://www.independent.co.uk/news/world/europe/west-nile-virus-climate-change-mosquito-germany-tropical-medicine-a9123601.html파일을 얻은 17/12/2019.

Conflict of Interest: BS carries out research and consulting projects for pharmaceutical firms and other public, private, charitable and community organisations.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Copyright © 2020 Shaw and Chisholm. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.